Long-term pharmacotherapy of obesity 2000: A review of efficacy and safety

Archives of Internal Medicine

Volumn 161, Issue 15, 2001, Pages 1814-1824

  Glazer, G ^a  

^a Genesee Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEPRAMONE; ANOREXIGENIC AGENT; FENFLURAMINE; PHENTERMINE; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BODY WEIGHT; DRUG EFFICACY; DRUG SAFETY; HUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; WEIGHT REDUCTION;

EID: 0034890568     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.15.1814     Document Type: Review

References (113)

1. Increasing prevalence of overweight among US adults
2. Long-term weight control study, 1 (weeks 0 to 34): The enhancement of behavior modification, caloric restriction, and exercise by fenfluramine plus phentermine versus placebo
3. Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services interim public health recommendations
4. The genetics of obesity
5. A brief overview of human energy metabolism and its relationship to essential obesity
6. Molecular genetics in clinical practice, XII: The genetics of obesity
7. The role of leptin in human obesity and disease: A review of current evidence
8. Divergent trends in obesity and fat intake patterns: The American paradox
9. Obesity in Britain: Gluttony or sloth?
10. Actual causes of death in the United States
11. Body weight and mortality among women
12. Overweight, underweight, and mortality: A prospective study of 48287 men and women
13. Medical hazards of obesity
14. Obesity/insulin resistance is associated with endothelial dysfunction
15. Elevated C-reactive protein levels in overweight and obese adults
16. Severe obesity: Expensive to society, frustrating to treat, but important to confront
17. Association between body mass and adenocarcinoma of the esophagus and gastric cardia
18. Liver fibrosis in overweight patients
19. Incidence and progression of osteoarthritis in women with unilateral knee disease in the general population: The effect of obesity
20. A prospective study of risk factors for pulmonary embolism in women
21. Thrombolytic therapy for pulmonary embolism: Is it effective? Is it safe? When is it indicated?
22. Safety and effectiveness of a multidisciplinary very-low-calorie diet program for selected obese individuals
23. Three-year follow-up of participants in a commercial weight loss program: Can you keep it off?
24. Long-term follow-up of patients attending a combination very-low calorie diet and behavior therapy weight loss programme
25. Thirty-month evaluation of a popular very-low-calorie diet program
26. A multicenter evaluation of a proprietary weight loss program for the treatment of marked obesity: A five-year follow-up source
27. Treatment of obesity by very-low-calorie diet, behavior therapy, and their combination: A five-year perspective
28. Minireview: Anorectic agents lower a body weight set point
29. The pharmacologic approach to the treatment of obesity
30. The long-term management of obesity in general practice
31. The use of diethylpropion in the treatment of obesity
32. Long-term use of diethylpropion in obesity
33. Diethylpropion in the treatment of "refractory" obesity
34. Mazindol in obesity with known cardiac disease: A clinical evaluation
35. Short-term and long-term clinical evaluation of a non-amphetaminic anorexiant (mazindol) in the treatment of obesity
36. Clinical studies with mazindol
37. Comparison of continuous and intermittent anorectic therapy in obesity
38. Long-term weight loss with sibutramine
39. Fluoxetine: A randomized clinical trial in the treatment of obesity
40. A double-blind clinical trial in weight control: Use of fenfluramine and phentermine alone and in combination
41. Phentermine resin as an adjunct in medical weight reduction: A controlled, randomized, double-blind prospective study
42. A comparative trial of different regimens of phentermine and fenfluramine in obesity
43. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat
44. Sibutramine - Dose response and long-term efficacy in weight loss, a double-blind study
45. Long-term maintenance of weight loss after a very-low-calorie diet: A ramdomized blinded trial of the efficacy and tolerability of sibutramine
46. Sibutramine - A review of clinical efficacy
47. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin)
48. Orlistat (Ro 18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study
49. Role of orlistat in the treatment of obese patients with type 2 diabetes: A 1-year randomized double-blind study
50. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients
51. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: A randomized controlled trial
52. Adiposity as a risk determinant for postmenopausal breast cancer
53. Metabolic profiles of minimally absorbed orlistat in obese/ overweight volunteers
54. DA 20-766. Xenical (Orlistat)
55. Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: A dose-response study
56. Efficacy and safety of long-term fluoxetine treatment of obesity-maximizing success
57. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters
58. Fluoxetine has potential in obese NIDDM - Multi-center Canadian Trial
59. Fluoxetine in the treatment of obese type 2 diabetic patients
60. Sertraline and relapse prevention training following treatment by very-low-calorie diet: A controlled clinical trial
61. Effects of fluoxetine, phentermine, and venlafaxine on pulmonary arterial pressure and electrophysiology
62. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability
63. Dexfenfluramine: An updated review of its therapeutic use in the management of obesity
64. The anorectic and hypotensive effect of fenfluramine in obesity
65. International trial of long-term dexfenfluramine in obesity
66. Dexfenfluramine in the treatment of severe obesity: A placebo-controlled investigation of the effects on weight loss, cardiovascular risk factors, food intake and eating behaviour
67. Valvular heart disease associated with fenfluramine-phentermine
68. Prevalence and clinical correlates of aortic and mitral regurgitation in a young adult population: The CARDIA study
69. Low prevalence of vavular heart disease in 226 phentermine-fenfluramine protocol subjects prospectively followed for up to 30 months
70. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine
71. Diet drug-related cardiac valve disease: The Mayo Clinic Echocardiographic Laboratory experience
72. Asymptomatic mitral and aortic valve disease is seen in half of patients taking "Phen-Fen"
73. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
74. Fenfluramine and phentermine and cardiovascular findings: Effect of treatment duration on prevalence of valve abnormalities
75. Prevalence and determinants of valvulopathy in patients treated with dexfenfluramine
76. The fen-phen finale: A study of weight loss and valvular heart disease
77. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo
78. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite suppressant drugs
79. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication
80. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine
81. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
82. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine
83. Regression of multivalvular regurgitation after the cessation of fenfluramine and phentermine treatment
84. Aortic and mitral valve disease induced by ergotamine therapy for migraine: A case report and review of the literature
85. Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine
86. The "Phen-Pro" diet drug combination is not associated with valvular heart disease
87. Absence of cardiac valve dysfunction in obese patients treated with sibutramine
88. The effects of anorectic agents on the pulmonary pressure and morphology of rat lungs after chronic administration
89. Anorexic agents aminorex, fenfluramine and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction
90. Phentermine resinate and the pulmonary vasculature of the rat
91. A characterization of the acute cardiopulmonary toxicity of fenfluramine in the rat
92. Appetite suppressant drugs and the risk of primary pulmonary hypertension
93. Effect of degree of weight loss on health benefits
94. Beneficial health effects of modest weight loss
95. The beneficial effects of modest weight loss on cardiovascular risk factors
96. What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes
97. Influences of cardiorespiratory fitness and other precursors on cardiovascular disease and all-cause mortality in men and women
98. Exercise as an adjunct to weight loss and maintenance in moderately obese subjects
99. The role of exercise in weight regulation in nonathletes
100. Energy expenditure with indoor exercise machines
101. How much physical activity is needed to minimize weight gain in previously obese women?
102. Similar weight loss with low- or high-carbohydrate diets
103. Effect of energy restriction, weight loss, and diet composition on plasma lipids and glucose in patients with type 2 diabetes
104. Weight loss with high and low carbohydrate 1200-kcal diets in free living women
105. Nonsurgical factors that influence the outcome of bariatric surgery: A review
106. Safe and effective management of the obese patient
107. Late results of gastric bypass surgery for morbid obesity
108. A new paradigm for type 2 diabetes mellitus: Could it be a disease of the foregut?
109. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus
110. Effect of coronary artery bypass surgery on survival: Results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration